Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats

Joong Kyung Sung, Jang Hyun Koh, Mi Young Lee, Bo Hwan Kim, Soo Min Nam, Jae Hyun Kim, Jin Hee Yoo, So Hee Kim, Sun Won Hong, Eun Young Lee, Ran Choi, Choon Hee Chung

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model. Materials and Methods: Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg ̇ kg-1 ̇ day-1) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg ̇ kg-1 ̇ day-1) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions. Results: The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 ± 11.12, 16.11 ± 9.95, and 84.85 ± 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. Conclusion: We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalYonsei medical journal
Volume51
Issue number3
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

Aldehyde Reductase
Streptozocin
Vascular Endothelial Growth Factor A
Losartan
Kidney
Diabetic Nephropathies
Control Groups
Albumins
Creatinine
Podocytes
Angiotensin Receptor Antagonists
Intraperitoneal Injections
Sprague Dawley Rats
Blood Glucose
Body Weight
Urine
Messenger RNA
fidarestat
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Sung, Joong Kyung ; Koh, Jang Hyun ; Lee, Mi Young ; Kim, Bo Hwan ; Nam, Soo Min ; Kim, Jae Hyun ; Yoo, Jin Hee ; Kim, So Hee ; Hong, Sun Won ; Lee, Eun Young ; Choi, Ran ; Chung, Choon Hee. / Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats. In: Yonsei medical journal. 2010 ; Vol. 51, No. 3. pp. 385-391.
@article{0821e37d45fe41dd8f418f41fad6412e,
title = "Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats",
abstract = "Purpose: The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model. Materials and Methods: Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg ̇ kg-1 ̇ day-1) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg ̇ kg-1 ̇ day-1) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions. Results: The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 ± 11.12, 16.11 ± 9.95, and 84.85 ± 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. Conclusion: We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.",
author = "Sung, {Joong Kyung} and Koh, {Jang Hyun} and Lee, {Mi Young} and Kim, {Bo Hwan} and Nam, {Soo Min} and Kim, {Jae Hyun} and Yoo, {Jin Hee} and Kim, {So Hee} and Hong, {Sun Won} and Lee, {Eun Young} and Ran Choi and Chung, {Choon Hee}",
year = "2010",
month = "5",
day = "1",
doi = "10.3349/ymj.2010.51.3.385",
language = "English",
volume = "51",
pages = "385--391",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Sung, JK, Koh, JH, Lee, MY, Kim, BH, Nam, SM, Kim, JH, Yoo, JH, Kim, SH, Hong, SW, Lee, EY, Choi, R & Chung, CH 2010, 'Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats', Yonsei medical journal, vol. 51, no. 3, pp. 385-391. https://doi.org/10.3349/ymj.2010.51.3.385

Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats. / Sung, Joong Kyung; Koh, Jang Hyun; Lee, Mi Young; Kim, Bo Hwan; Nam, Soo Min; Kim, Jae Hyun; Yoo, Jin Hee; Kim, So Hee; Hong, Sun Won; Lee, Eun Young; Choi, Ran; Chung, Choon Hee.

In: Yonsei medical journal, Vol. 51, No. 3, 01.05.2010, p. 385-391.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats

AU - Sung, Joong Kyung

AU - Koh, Jang Hyun

AU - Lee, Mi Young

AU - Kim, Bo Hwan

AU - Nam, Soo Min

AU - Kim, Jae Hyun

AU - Yoo, Jin Hee

AU - Kim, So Hee

AU - Hong, Sun Won

AU - Lee, Eun Young

AU - Choi, Ran

AU - Chung, Choon Hee

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model. Materials and Methods: Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg ̇ kg-1 ̇ day-1) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg ̇ kg-1 ̇ day-1) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions. Results: The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 ± 11.12, 16.11 ± 9.95, and 84.85 ± 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. Conclusion: We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.

AB - Purpose: The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model. Materials and Methods: Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg ̇ kg-1 ̇ day-1) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg ̇ kg-1 ̇ day-1) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions. Results: The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 ± 11.12, 16.11 ± 9.95, and 84.85 ± 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. Conclusion: We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.

UR - http://www.scopus.com/inward/record.url?scp=77954296340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954296340&partnerID=8YFLogxK

U2 - 10.3349/ymj.2010.51.3.385

DO - 10.3349/ymj.2010.51.3.385

M3 - Article

VL - 51

SP - 385

EP - 391

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -